Privia Health Group, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied text does not provide clear standalone fourth-quarter results.
Business context
Privia is a physician-enablement company that provides technology, practice management and clinical support to medical groups, and participates in fee-for-service (FFS) and value-based care (VBC) arrangements. At year-end, it reported 4,305 implemented providers, 1.12 million attributed lives in VBC programs, and more than 1,090 care-center locations. Revenue includes FFS patient care, administrative services, capitated care, shared savings and care-management fees.
Financial and operating results
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $1,657.7 million | $1,356.7 million | +22.2% |
| Operating income (loss) | $20.6 million | $(19.1) million | Improved $39.8 million |
| Net income (loss) attributable to Privia | $23.1 million | $(8.6) million | Improved $31.7 million |
| Diluted earnings (loss) per share | $0.19 | $(0.08) | Turned positive |
| Net cash from operating activities | $80.8 million | $47.2 million | +$33.6 million |
| Cash and cash equivalents at year-end | $389.5 million | $348.0 million | +$41.5 million |
| Debt outstanding | $0 | — | No borrowings at year-end |
- Revenue growth reflected higher capitation revenue (+55.1% to $338.7 million), FFS patient-care revenue (+12.4% to $976.7 million), shared savings (+28.3% to $170.1 million), and care-management fees (+42.1% to $50.5 million). Capitation and shared-savings revenue together represented a larger share of reported revenue than in 2022.
- Provider expense rose 23.6% to $1,298.6 million, faster than total revenue. Gross profit was $353.8 million, approximately 21.3% of revenue. Management’s non-GAAP Care Margin was $359.2 million, or 21.7% of revenue, versus $305.6 million, or 22.5%, in 2022.
- Non-GAAP Platform Contribution was $173.5 million, up 16.8%; its margin was 48.3% of Care Margin, compared with 48.6%. Adjusted EBITDA was $72.2 million, up 18.7%, and Adjusted EBITDA Margin was 20.1% of Care Margin, versus 19.9%. These are company-defined non-GAAP measures and should be considered alongside GAAP results.
- Cash flow from operations increased, but accounts receivable also rose to $290.8 million from $189.6 million. Provider liability increased to $326.1 million from $208.4 million, including $67.1 million of estimated unpaid medical claims under at-risk capitation arrangements.
- Current assets were $700.8 million and current liabilities were $387.0 million at year-end. The company reported a $125 million revolving credit facility established in November 2023, with no amount drawn at year-end. Substantially all real and personal property secures the facility.
Changes, outlook and notable items
- Privia returned to GAAP profitability in 2023 after losses in 2022 and 2021. The improvement included lower stock-based compensation expense: $37.1 million in 2023 versus $67.4 million in 2022. General and administrative expense fell 15.4%, mainly because certain pre-IPO options had fully vested in late 2022.
- Provider count increased 19.4% and attributed lives increased 30.8% year over year. The company entered Connecticut, Washington state and South Carolina and reported investment-related cash outflows of $42.9 million, primarily for acquisitions and new markets.
- Management did not provide a specific 2024 revenue or earnings forecast in the supplied filing text. It described continued investment in growth, technology, sales and marketing, and expanded clinical capabilities as it pursues new markets and moves providers toward VBC.
- Management said it was renegotiating certain Medicare Advantage capitation contracts amid higher medical-cost trends and reimbursement pressures, seeking structures with positive contribution margins and less downside risk. The filing gives differing estimates for lives expected to shift from capitation to shared savings—approximately 19,900 in one discussion and a reduction from about 35,900 to 16,000 capitated lives in another. The exact expected impact should be verified.
- The company planned to exit its Delaware ACO. The filing describes different effective dates in different sections; the timing and related impact should be verified. It also described nine ACOs serving approximately 192,000 Medicare beneficiaries for the 2024 MSSP performance year.
- Key risks include extensive healthcare regulation, state corporate-practice-of-medicine and fee-splitting rules, payer reimbursement and contract changes, accuracy of Medicare Advantage risk-adjustment coding, VBC cost and claims estimates, provider recruitment and retention, competition, cybersecurity and privacy, and dependence on athenahealth as the underlying EMR vendor. The filing reports no known cybersecurity risks that had materially affected, or were reasonably likely to materially affect, the company.
- The auditor identified critical audit matters involving valuation of FFS accounts receivable, Medicare Shared Savings Program revenue, and unpaid medical claims under at-risk capitation. Management and the auditor reported effective internal control over financial reporting as of December 31, 2023. The company stated there were no material commitments or contingencies and did not believe current legal matters were reasonably likely to have a material adverse effect.
Important facts for investors to verify
- Reconcile the stated 2024 capitation-contract transition estimates and confirm the final number of affected lives, contract economics and expected contribution-margin effects.
- Confirm the Delaware ACO exit’s effective date and implications for 2024 attributed lives, revenue and shared-savings participation.
- Track medical-cost trends, unpaid-claims estimates and cash conversion as at-risk capitation grows; compare provider-liability development with subsequent claims payments.
- Assess whether growth in revenue and attributed lives translates into stronger GAAP operating margins and cash flow, given provider expenses rose faster than revenue and receivables increased.
- Monitor payer concentration: three payers accounted for 56% of 2023 revenue, with the largest at 30%; the largest accounted for 23% of year-end receivables.
- Review acquisition performance, the costs of new-market expansion, and the remaining implementation pipeline; new providers typically take several months to go live.